PACB
Pacific Biosciences of CaliforniaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Composite grade D from latest DB weights. Momentum 45.1 / Value 41.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
45
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $2.46
Why
Momentum45 · Δ7d -
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
45
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 45.1 / Value 41.1
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$422.42M
Beta
2.26
Shares Out
310.6M
P/E (TTM) · Derived
-0.7
P/S (TTM)
3.87
P/FCF (TTM) · Derived
-3.54
Rev YoY
+0.1%
EPS YoY
-98.1%
Gross Margin
+38.2%
Op Margin
-330.7%
Net Debt
$422.9M
Current Ratio
5.65
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology